How AI, Precision Medicine, and Biologics Are Transforming Asthma and COPD Management: Insights from 50 Respiratory KOLs Across the US and Europe
Insights from 50 Respiratory Key Opinion Leaders across the United States and Europe on biologics, precision medicine, AI-powered respiratory care, biomarker-guided treatment, smart inhalers, digital health, and the future of asthma and COPD management.
To assess expert perceptions regarding evolving asthma and COPD management, adoption of biologics and targeted therapies, biomarker-guided treatment, digital health technologies, personalized medicine, implementation challenges, and future directions in respiratory care.
AI, Precision Medicine, and Biologics Are Redefining Respiratory Care
Asthma and Chronic Obstructive Pulmonary Disease (COPD) continue to place a substantial clinical and economic burden on healthcare systems worldwide. Although inhaled therapies and disease management strategies have improved outcomes for many patients, uncontrolled symptoms, frequent exacerbations, and progressive lung function decline remain major challenges.
Advances in biologics, precision medicine, biomarker-guided therapy, artificial intelligence, smart inhalers, remote patient monitoring, and digital therapeutics are transforming respiratory care by enabling highly personalized treatment strategies and proactive disease management.
To better understand these evolving respiratory healthcare trends, a recent respiratory market research study surveyed 50 respiratory Key Opinion Leaders (KOLs) across the United States and Europe to capture expert perspectives on biologics, AI-powered respiratory care, precision medicine, digital health technologies, implementation challenges, and the future of asthma and COPD management.
Respiratory experts emphasize biologics, precision medicine, biomarker-guided treatment, AI-powered clinical decision support, digital health, and connected respiratory devices to improve patient outcomes.
AI, smart inhalers, remote patient monitoring, biologics, predictive analytics, and personalized respiratory care are expected to define the next generation of asthma and COPD management.
Key Survey Highlights
Respiratory KOLs demonstrate strong confidence in biologics, biomarker-driven precision medicine, AI-powered respiratory care, and digital health technologies as the future of asthma and COPD management.
Believe continued innovation in asthma and COPD management remains a high priority for improving respiratory care.
Consider biomarkers and personalized medicine essential for optimizing asthma and COPD treatment decisions.
Expect widespread adoption of biologics, AI-supported respiratory care, and digital monitoring within the next five years.
Are optimistic that AI, biologics, precision medicine, and connected respiratory technologies will transform long-term respiratory care.
Asthma and COPD management continue to face significant clinical challenges
Despite advances in inhaled therapies and disease management, many patients continue to experience uncontrolled symptoms, frequent exacerbations, and declining lung function. Respiratory specialists believe innovation remains essential for improving long-term outcomes.
The respiratory KOL survey found that 88% of experts believe continued innovation is highly necessary, while 80% feel current treatment options are only partially adequate for meeting the needs of asthma and COPD patients.
These findings reinforce the growing importance of biologics, biomarker-guided therapy, AI-powered clinical decision support, digital health technologies, smart inhalers, and personalized medicine for delivering more effective respiratory care.
Uncontrolled disease
Many asthma and COPD patients continue to experience frequent exacerbations despite current treatment approaches.
High treatment costs
The cost of advanced biologics and targeted therapies remains a significant barrier to broader patient access.
Biomarker accessibility
Limited access to biomarker testing continues to slow the adoption of precision medicine in respiratory care.
Patient adherence
Poor adherence to inhaled medications remains one of the leading causes of uncontrolled respiratory disease.
AI integration
Successfully integrating AI, remote monitoring, and digital respiratory platforms into routine clinical practice requires interoperability and clinician confidence.
Healthcare infrastructure
Reimbursement policies, healthcare infrastructure, and equitable access continue to influence the adoption of advanced respiratory therapies.
Survey Results Summary
The respiratory KOL survey provides valuable insights into biologics, precision medicine, biomarker-guided treatment, AI-powered respiratory care, digital health technologies, and the future of asthma and COPD management.
Respiratory experts remain optimistic that AI, biologics, precision medicine, and digital health technologies will transform asthma and COPD management over the next decade.
Believe continued innovation is essential for improving asthma and COPD management.
Say existing treatment options are only partially adequate for meeting patient needs.
Consider biomarkers and personalized medicine extremely important for optimizing respiratory care.
Expect biologics, AI, and digital respiratory monitoring to expand substantially within five years.
Most Common Response by Question
Continued innovation remains essential
Most respiratory specialists believe asthma and COPD require continued therapeutic and technological innovation.
Current therapies are only partially adequate
Most KOLs believe additional therapeutic innovation is needed to improve disease control and long-term outcomes.
Biologics and precision medicine lead innovation
Experts identified biologics, precision medicine, and triple inhaled therapies as the most significant recent advancements.
Biomarker-guided care is critical
Biomarkers and personalized medicine are considered essential for selecting targeted respiratory therapies.
AI and biologics will rapidly expand
Most experts expect biologics, digital monitoring, and AI-supported respiratory care to become standard practice within five years.
Cost and access remain major barriers
High treatment costs, limited access, and patient adherence continue to restrict broader adoption of advanced respiratory therapies.
AI will improve respiratory outcomes
AI, digital health, and remote monitoring are expected to improve disease prediction, medication adherence, and patient outcomes.
Future outlook remains highly optimistic
Respiratory specialists are confident that AI, biologics, precision medicine, and connected care will redefine asthma and COPD management.
Response Distribution by Question
The detailed survey responses provide valuable respiratory market insights into biologics, precision medicine, biomarker-guided treatment, AI-powered respiratory care, digital health technologies, and the future of asthma and COPD management.
Q1 – Q4
Q5 – Q8
The Future of Asthma and COPD Management Is Intelligent, Personalized, and Connected
This respiratory KOL survey demonstrates that asthma and COPD management is entering a new era driven by biologics, precision medicine, artificial intelligence, biomarker-guided therapies, and digital health technologies. Insights gathered from 50 respiratory Key Opinion Leaders across the United States and Europe highlight growing confidence that personalized treatment strategies will significantly improve patient outcomes while reducing exacerbations and healthcare burden.
For organizations involved in respiratory market research, pulmonary healthcare innovation, asthma and COPD therapeutics, digital respiratory health, and respiratory market intelligence, these findings provide valuable strategic direction for future investment and product development. Experts consistently identified biologics, AI-powered clinical decision support, smart inhalers, predictive analytics, and remote patient monitoring as the innovations most likely to transform respiratory medicine.
As adoption of biomarker-guided treatment, connected respiratory devices, artificial intelligence, and precision medicine continues to accelerate, healthcare organizations that embrace these innovations while addressing cost, access, reimbursement, and interoperability challenges will be best positioned to deliver more personalized, efficient, and value-based respiratory care.
Strategic Takeaway
Organizations investing in biologics, AI-powered respiratory care, biomarker-guided precision medicine, digital health platforms, smart inhalers, remote patient monitoring, and respiratory market intelligence will gain a competitive advantage as asthma and COPD management becomes increasingly personalized, predictive, and data-driven.
